The study explores the interconnected risks between COVID-19 and Alzheimer’s Disease (AD), highlighting how SARS-CoV-2 can aggravate AD pathology through neuroinflammation and neurodegeneration. It raises significant concerns about the long-term cognitive implications of COVID-19, especially among those already at risk for AD.
Experimental drug shows promise in restoring memory in Alzheimer’s model
A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive
February 5, 2025